영문뉴스

JLK Shares Soar on Expansion of Brain Imaging AI Solutions…Quadmedicine·Aimedbio↑[K-bio Pulse]

created on 12/15/2025 8:00:05 AM
modified on 12/15/2025 8:00:05 AM

This article was released as Pharm Edaily Premium Content on 12/15/2025 8:00:05 AM Subscribe

Unauthorized reproduction or distribution is illegal and subject to criminal penalties.
Pharm Edaily enforces a zero-tolerance policy and will take strict action.

[Shin-Min Joon, Edaily Reporter] On the 12th in the domestic pharmaceutical and biotech market, shares of JLK surged. Expectations surrounding the expansion of JLK‘s brain imaging AI subscription service and other solutions helped drive the stock price upward.

Quadmedicine which debuted on the KOSDAQ market, saw its stock price rise by double digits compared to its IPO price. The company drew attention for its medical microneedle platform which offers a novel drug delivery method that addresses the limitations of traditional injections and oral medications.

Aimedbio the only bio firm backed by Samsung also attracted strong buying interest amid expectations for its development of antibody-drug conjugate (ADC) therapeutics.

JLK Intensifies Brain Imaging AI Subscription Service

According to KG Zeroin’s MP DOCTOR (formerly Market Point), JLK‘s stock price surged 26.69 percent from the previous day to close at 5980 won. The news that JLK signed a subscription service agreement for its brain imaging AI with Hallym University Sacred Heart Hospital had a positive impact on the share price.

JLK is moving forward with its subscription based brain imaging AI service by signing a contract to supply AI software for brain image analysis with Hallym University Sacred Heart Hospital.

Under the contract JLK will provide four digital medical device software products approved by the Ministry of Food and Drug Safety to Hallym University Sacred Heart Hospital JLK-LVO, JLK-CTP, JLK-CTL, and JLK-PWI.

JLK-LVO analyzes computed tomography angiography (CTA) brain images using AI to detect the presence of large vessel occlusion (LVO), identify suspected blockage locations, and automatically calculate vessel volumes.

JLK-LVO was designated for integrated review as an innovative medical device in April and is proceeding with the process to obtain non covered medical fees.

JLK-CTP and JLK-PWI calculate the core infarct and hypoperfused regions from brain computed tomography perfusion (CTP) and magnetic resonance imaging (MRI), respectively and provide information on discrepancies between the two measures.

JLK-CTL automatically analyzes low-attenuation regions in non contrast CT (NCCT) images to deliver brain imaging information. JLK plans to expand its brain imaging AI subscription service across hospitals nationwide.

A JLK representative said “This contract is significant as it introduces a subscription model that allows continuous use of AI software in hospital settings over a defined period. Based on a structure that supports regular updates and maintenance, medical institutions can adopt AI solutions without initial cost burdens.”

JLK is also expanding overseas. The company is pursuing entry into both the Japanese and U.S. markets. JLK has seven brain imaging AI solutions approved by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.

These solutions support full-cycle diagnosis using key brain imaging modalities, covering microbleeds, acute ischemic stroke, perfusion disorders, and decisions on reperfusion procedures.

Each solution is tailored to specific imaging modalities such as MRI and CT. Their ability to meet the diverse brain disease interpretation needs of Japanese hospitals is considered a strength. The Japanese AI medical market is projected to reach 8.9 billion dollars (about 13 trillion won) by 2030.

JLK has completed U.S. Food and Drug Administration (FDA) approval applications for the JLK-LVO, JLK-CTP, and JLK-PWI solutions. The company aims to achieve 600 billion won in U.S. sales by 2028.

To capture market share in the U.S., JLK also launched SNAPPY, an integrated mobile healthcare app platform. Through the mobile app, SNAPPY can reduce preoperative time by up to three hours.

Quadmedicine’s Medical Microneedle Platform Gains Attention

On the same day newly listed KOSDAQ stock Quadmedicine closed at 17 639 won up 17.53 percent from its IPO price of 15 000 won. Although the share price rose as high as 26 800 won early in trading, its gains narrowed during the session.

Quadmedicine a company specializing in medical microneedle platforms is expected to address limitations of conventional injections and oral drugs.

The company‘s skin delivery-based microneedle technology falls into three categories the separable microneedle S-MAP, coated microneedle C-MAP, and particle-attached microneedle P-MAP.

S-MAP features a drug-containing tip that separates from the supporting base upon skin application leaving no residue and enabling high convenience and rapid drug delivery.

C-MAP has a drug coated layer that dissolves in bodily fluids, providing heat stability and ease of distribution and storage. P-MAP is an extension of C-MAP that attaches freeze-dried micronized vaccine to the needle tip.

Each technology offers characteristics such as minimal invasiveness ease of self administration and room temperature stability. Accordingly the platform can be applied to a variety of formulations including vaccines, peptides and synthetic drugs.

When repurposed as reformulated improved drugs or biobetters existing approved drugs may be able to skip parts of Phase 2 and Phase 3 clinical trials after Phase 1 enabling faster commercialization.

With funds raised through its listing, Quadmedicine plans to accelerate development of drugs such as obesity treatments and vaccines using microneedle drug delivery technology.

The company is jointly developing a microneedle osteoporosis treatment with Hanlim Pharm and obesity and acute allergy treatments with Hanlim Pharm’s affiliate Sangmyung Innovation.

For a hepatitis B vaccine Quadmedicine is conducting Phase 1 clinical trials in Korea with LG Chem. After completing domestic Phase 1 trials, the company plans to prepare an investigational new drug (IND) application to begin global Phase 1/2 trials next year.

Since 2022 Quadmedicine has also collaborated with GlaxoSmithKline (GSK) on preclinical research that applies its microneedle technology to GSK‘s Shigella vaccine.

Quadmedicine is also commercializing a contract development and manufacturing organization (CDMO) model to boost performance.

A Quadmedicine representative said “Expectations for microneedle pharmaceuticals appear to have positively influenced our stock price. Quadmedicine will continue to do its best to enhance corporate value.”

Aimedbio Seeks Follow-On Technology Licensing Opportunities

Aimedbio’s share price closed at 55 900 won, up 19.70 percent from the previous day. The company is seen as emerging into a top tier player in the antibody drug conjugate (ADC) new drug development field. Aimedbio uses patient derived cancer cells to precisely discover antibodies and has co developed optimized payloads with Samsung Biologics.

Since 2023 Aimedbio and Samsungbiologics have jointly developed an ADC toolbox. The ADC toolbox refers to the internalized ADC technologies, platforms, and know how that a contract development and manufacturing organization (CDMO) retains for client use.

Before going public Aimedbio had already achieved more than 3 trillion won in cumulative technology licensing deals. It licensed AMB302 for bladder cancer to Biohaven in the U.S. and ODS025 for target overexpressing solid tumors to Boehringer Ingelheim in Germany.

AMB303 licensed to SK Plasma incorporates a next generation payload co developed by Aimedbio and Samsungbiologics a camptothecin class topoisomerase-1 (Topo-1) inhibitor.

Aimedbio is preparing the clinical trial application (IND) for AMB302 and its follow on drug pipeline. At the JP Morgan Healthcare Conference scheduled for January next year meetings are planned with partners including Boehringer Ingelheim, Biohaven, Samsungbiologics and SK Plasma.

An Aimedbio representative said “We expect continued entry of follow on drug clinical trials and milestone revenues next year. Aimedbio also plans to pursue additional technology licensing opportunities with other global companies.”

신민준 기자 adonis@: 지난해 흑자전환 성공한 지엘팜텍, 실적 퀀텀점프 복안은?; 온코닉테라퓨틱스, 올해 매출·영업익 더블업 성장 자신하는 이유; "美진출하려면 中임상해도 美환자 최소 20% 참여해야"[제약·바이오 해외토픽]